



Report Name: PAA_ANNUALLY_NIPPON_IN_STATISTICS_RISK_CLASS

Report Run Date Range: Resolution Date between 1/1/2025 and 12/31/2025 11:59:59 PM Central Time

Report Definition: A summary of client activity with total for the calendar.

Produced by: Prior Authorization and Appeals Reporting

Run Date: 01/21/2026 3:07:12 PM

Report Owner: NIPPON/ Developer: JJ

CVS Caremark Proprietary and Confidential PBM Member Services Reporting

PA CLASS	APPROVALS	DENIALS	NO RESPONSE	URGENT	STANDARD	TOTAL	% APPROVALS	% DENIALS	% NO RESPONSE	% URGENT	% STANDARD
Initial Benefit Review (NonClinic)	0	15	2	3	14	17	0.00%	88.24%	11.76%	17.65%	82.35%
SABAs (FA-PA)	0	7	0	0	7	7	0.00%	100.00%	0.00%	0.00%	100.00%
Skyrizi SGM*	2	0	1	0	3	3	66.67%	0.00%	33.33%	0.00%	100.00%
Praluent, Repatha, Leqvio FE SSPA*	2	1	0	1	2	3	66.67%	33.33%	0.00%	33.33%	66.67%
Humira and biosimilars FE SGM	1	1	1	1	2	3	33.33%	33.33%	33.33%	33.33%	66.67%
Opioids IR - 7-Day APAP-ASA-IBU Combo Products - Acute Pain Duration Limit	3	0	0	1	2	3	100.00%	0.00%	0.00%	33.33%	66.67%
ED-BPH PDE-5 Inhibitors PA with Limit	0	2	1	1	2	3	0.00%	66.67%	33.33%	33.33%	66.67%
Multiple Sclerosis Gilenya, Tascenso ODT, [fingolimod] FE SGM	1	0	1	0	2	2	50.00%	0.00%	50.00%	0.00%	100.00%
Revatio, Liqrev [sildenafil] FE SGM	1	0	1	0	2	2	50.00%	0.00%	50.00%	0.00%	100.00%
Sotyktu SGM*	1	0	1	0	2	2	50.00%	0.00%	50.00%	0.00%	100.00%
Botox FE SGM*	1	0	1	0	2	2	50.00%	0.00%	50.00%	0.00%	100.00%
Cosentyx FE SGM	1	0	1	0	2	2	50.00%	0.00%	50.00%	0.00%	100.00%
Rapid Acting Insulin Products (FA-PA)	0	1	1	0	2	2	0.00%	50.00%	50.00%	0.00%	100.00%
Fluticasone-Salmeterol Diskus NTM (FA-PA)	0	2	0	0	2	2	0.00%	100.00%	0.00%	0.00%	100.00%
Auvelity(FA-PA)	1	0	1	0	2	2	50.00%	0.00%	50.00%	0.00%	100.00%
Tryptyr NTM (FA-PA)	0	1	1	1	1	2	0.00%	50.00%	50.00%	50.00%	50.00%
Anaphylaxis Treatment (FA-PA)	0	0	2	0	2	2	0.00%	0.00%	100.00%	0.00%	100.00%
Rinvoq, Rinvoq LQ AD Enhanced SGM	0	0	1	0	1	1	0.00%	0.00%	100.00%	0.00%	100.00%
Dupixent AD Enhanced SGM	1	0	0	0	1	1	100.00%	0.00%	0.00%	0.00%	100.00%
Insulin Aspart NTM (FA-PA)	0	0	1	1	0	1	0.00%	0.00%	100.00%	100.00%	0.00%
Nasal Steroids (FA-PA)	1	0	0	0	1	1	100.00%	0.00%	0.00%	0.00%	100.00%
Tretinoin Products	1	0	0	0	1	1	100.00%	0.00%	0.00%	0.00%	100.00%
Carafate (FA-PA)	0	0	1	0	1	1	0.00%	0.00%	100.00%	0.00%	100.00%
Urinary Antispasmodics (FA-PA)	1	0	0	0	1	1	100.00%	0.00%	0.00%	0.00%	100.00%
Proton Pump Inhibitors (FA-PA)	0	1	0	0	1	1	0.00%	100.00%	0.00%	0.00%	100.00%
Antidiabetic GLP-1, GIP-GLP-1 Agonist PA with Logic	0	1	0	0	1	1	0.00%	100.00%	0.00%	0.00%	100.00%
Suboxone Film (FA-PA)	0	0	1	1	0	1	0.00%	0.00%	100.00%	100.00%	0.00%
Long Acting Insulin (FA-PA)	0	1	0	0	1	1	0.00%	100.00%	0.00%	0.00%	100.00%
Global Post Step Therapy Indiana Mandate REG	1	0	0	0	1	1	100.00%	0.00%	0.00%	0.00%	100.00%
Opioids IR - 7-Day Acute Pain Duration Limit with MME Limit and Post Limit	1	0	0	0	1	1	100.00%	0.00%	0.00%	0.00%	100.00%
Insulin Glargine NTM (FA-PA)	0	1	0	0	1	1	0.00%	100.00%	0.00%	0.00%	100.00%
ADHD Agents (FA-PA)	1	0	0	1	0	1	100.00%	0.00%	0.00%	100.00%	0.00%
Zirgan (FA-PA)	0	1	0	0	1	1	0.00%	100.00%	0.00%	0.00%	100.00%
TOTAL	21	35	19	11	64	75	28.00%	46.67%	25.33%	14.67%	85.33%